CDK4 amplification predicts recurrence of well-differentiated liposarcoma of the abdomen

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Lee, Sanghoon ^a   Park, Hyojun ^a   Ha, Sang Yun ^a   Paik, Kwang Yeol ^b   Lee, Seung Eun ^a   Kim, Jong Man ^a   Park, Jae Berm ^a   Kwon, Choon Hyuck David ^a   Joh, Jae Won ^a   Choi, Yoon La ^a   Kim, Sung Joo ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 4; PROTEIN MDM2;

ABDOMINAL NEOPLASMS; ADULT; AGED; CANCER GRADING; FEMALE; GENE AMPLIFICATION; GENETICS; HUMAN; LIPOSARCOMA; MALE; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; TREATMENT OUTCOME; TUMOR RECURRENCE; TUMOR VOLUME;

ABDOMINAL NEOPLASMS; ADULT; AGED; CYCLIN-DEPENDENT KINASE 4; FEMALE; GENE AMPLIFICATION; HUMANS; LIPOSARCOMA; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MDM2; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84905993925     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0099452     Document Type: Article

References (21)

1. Dei Tos AP (2000) Liposarcoma: new entities and evolving concepts. Ann Diagn Pathol 4: 252-266.
2. Lewis JJ, Leung D, Woodruff JM, BrennanMF (1998) Retroperitoneal soft-tissue sarcoma: analysis of 500 patients treated and followed at a single institution. Ann Surg 228: 355-365. (Pubitemid 30191698)
3. Evans HL, Soule EH, Winkelmann RK (1979) Atypical lipoma, atypical intramuscular lipoma, and well differentiated retroperitoneal liposarcoma: a reappraisal of 30 cases formerly classified as well differentiated liposarcoma. Cancer 43: 574-584. (Pubitemid 9122282)
4. Hoffman A, Lazar AJ, Pollock RE, Lev D (2011) New frontiers in the treatment of liposarcoma, a therapeutically resistant malignant cohort. Drug Resist Updat 14: 52-66.
5. Pedeutour F, Suijkerbuijk RF, Forus A, Van Gaal J, Van de Klundert W, et al. (1994) Complex composition and co-amplification of SAS and MDM2 in ring and giant rod marker chromosomes in well-differentiated liposarcoma. Genes Chromosomes Cancer 10: 85-94. (Pubitemid 24155978)
6. Italiano A, Bianchini L, Gjernes E, Keslair F, Ranchere-Vince D, et al. (2009) Clinical and biological significance of CDK4 amplification in well-differentiated and dedifferentiated liposarcomas. Clin Cancer Res 15: 5696-5703.
7. Malumbres M, Barbacid M (2009) Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 9: 153-166.
8. Binh MB, Garau XS, Guillou L, Aurias A, Coindre JM (2006) Reproducibility of MDM2 and CDK4 staining in soft tissue tumors. Am J Clin Pathol 125: 693-697.
9. Aleixo PB, Hartmann AA, Menezes IC, Meurer RT, Oliveira AM (2009) Can MDM2 and CDK4 make the diagnosis of well differentiated/dedifferentiated liposarcoma? An immunohistochemical study on 129 soft tissue tumours. J Clin Pathol 62: 1127-1135.
10. Sirvent N, Coindre JM, Maire G, Hostein I, Keslair F, et al. (2007) Detection of MDM2-CDK4 amplification by fluorescence in situ hybridization in 200 paraffin-embedded tumor samples: utility in diagnosing adipocytic lesions and comparison with immunohistochemistry and real-time PCR. Am J Surg Pathol 31: 1476-1489. (Pubitemid 47482460)
11. Fletcher CD, Akerman M, Dal Cin P, de Wever I, Mandahl N, et al. (1996) Correlation between clinicopathological features and karyotype in lipomatous tumors. A report of 178 cases from the Chromosomes and Morphology (CHAMP) Collaborative Study Group. Am J Pathol 148: 623-630. (Pubitemid 26056746)
12. Meis-Kindblom JM, Sjogren H, Kindblom LG, Peydro-Mellquist A, Roijer E, et al. (2001) Cytogenetic and molecular genetic analyses of liposarcoma and its soft tissue simulators: recognition of new variants and differential diagnosis. Virchows Arch 439: 141-151. (Pubitemid 32758907)
13. Barretina J, Taylor BS, Banerji S, Ramos AH, Lagos-Quintana M, et al. (2010) Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet 42: 715-721.
14. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B (1992) Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358: 80-83.
15. Italiano A, Bianchini L, Keslair F, Bonnafous S, Cardot-Leccia N, et al. (2008) HMGA2 is the partner of MDM2 in well-differentiated and dedifferentiated liposarcomas whereas CDK4 belongs to a distinct inconsistent amplicon. Int J Cancer 122: 2233-2241. (Pubitemid 351542325)
16. Louis-Brennetot C, Coindre JM, Ferreira C, Perot G, Terrier P, et al. (2011) The CDKN2A/CDKN2B/CDK4/CCND1 pathway is pivotal in well-differentiated and dedifferentiated liposarcoma oncogenesis: an analysis of 104 tumors. Genes Chromosomes Cancer 50: 896-907.
17. Dickson MA, Keohan ML, Tap WD, Antonescu C, Landa J, et al. (2012) Phase II trial of the CDK4 inhibitor PD0332991 in CDK4-amplified liposarcoma. J Clin Oncol 30 (Suppl): abstr 10002.
18. Pilotti S, Della Torre G, Mezzelani A, Tamborini E, Azzarelli A, et al. (2000) The expression of MDM2/CDK4 gene product in the differential diagnosis of well differentiated liposarcoma and large deep-seated lipoma. Br J Cancer 82: 1271-1275. (Pubitemid 30145344)
19. Kim HS, Lee J, Yi SY, Jun HJ, Choi YL, et al. (2009) Liposarcoma: exploration of clinical prognostic factors for risk based stratification of therapy. BMC Cancer 9: 205.
20. Neuhaus SJ, Barry P, Clark MA, Hayes AJ, Fisher C, et al. (2005) Surgical management of primary and recurrent retroperitoneal liposarcoma. Br J Surg 92: 246-252. (Pubitemid 40269344)
21. Singer S, Antonescu CR, Riedel E, Brennan MF (2003) Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma. Ann Surg 238: 358-370; discussion 370-351.